Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 311-320 of 3418 for cancer

Edit search filters
  1. Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer

    Rochester, MN, Scottsdale/Phoenix, AZ, Jacksonville, FL

  2. Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer

    Scottsdale/Phoenix, AZ

  3. Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

    La Crosse, WI

  4. A Study of Rociletinib (CO-1686) for Patients with a Mutant form of Non-Small Cell Lung Cancer.

    Scottsdale/Phoenix, AZ

  5. A Study to Evaluate the Effects of Exercise on Fatigue in Thyroid Cancer Survivors

    Rochester, MN

  6. A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab

  7. A Safety Study of SGN-LIV1A in Breast Cancer Patients

    Rochester, MN

  8. RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

    Scottsdale/Phoenix, AZ

  10. Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer